What is Paroxysmal nocturnal hemoglobinuria?
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder characterized by the destruction of red blood cells, leading to anemia, blood clots, and organ damage. Despite its name suggesting nighttime symptoms, PNH causes continuous hemolysis (red blood cell breakdown) throughout the day. This acquired condition affects approximately 1 to 1.5 people per million globally, with symptoms typically appearing in adulthood between ages 20-50. PNH results from a genetic mutation that occurs spontaneously in bone marrow stem cells, making red blood cells vulnerable to destruction by the body’s own immune system.
Key statistics
| Prevalence: | 1-1.5 per million people worldwide |
| Peak onset age: | 20-50 years (mean age 35-42) |
| Sex distribution: | Affects men and women equally |
| 5-year survival: | 80-90% with modern treatment (previously 50%) |
Symptoms
Primary symptoms: Dark red or brown urine (hemoglobinuria), extreme fatigue, shortness of breath, blood clots, frequent infections, easy bruising, abdominal pain, difficulty swallowing, erectile dysfunction in men.
Early symptoms often include unexplained fatigue and weakness that interferes with daily activities. Patients may notice dark-colored urine, particularly in the morning, though this classic sign occurs in only 25-50% of cases. Shortness of breath during routine activities and pale skin may develop as anemia worsens.
Common ongoing symptoms include chronic fatigue that doesn’t improve with rest, frequent headaches, chest pain, and abdominal discomfort. Many patients experience difficulty concentrating and memory problems. Smooth muscle dysfunction can cause trouble swallowing (dysphagia) and digestive issues.
Serious complications involve blood clots (thrombosis) that can occur in unusual locations like abdominal veins, brain vessels, or liver veins. These clots represent the leading cause of death in PNH. Severe anemia may require blood transfusions, while kidney damage can develop from chronic hemoglobin exposure.
Causes and risk factors
PNH is caused by an acquired somatic mutation in the PIGA gene within bone marrow stem cells. This mutation occurs spontaneously and is not inherited from parents or passed to children. The PIGA gene normally produces proteins that anchor protective molecules to cell surfaces. When mutated, red blood cells lack these protective proteins (CD55 and CD59), making them susceptible to destruction by complement proteins in the blood.
The mutation creates a clone of abnormal stem cells that produce defective blood cells. Over time, these abnormal cells can outcompete normal cells, though the reasons for this selective advantage remain unclear.
Risk factors include having aplastic anemia or myelodysplastic syndrome, as PNH can develop in patients with these bone marrow disorders. However, most PNH cases occur spontaneously without identifiable risk factors. There is no evidence linking PNH to environmental exposures, infections, or lifestyle factors.
Prevention
No prevention strategies exist for PNH since it results from spontaneous genetic mutations that occur randomly in bone marrow cells. The condition is acquired rather than inherited, so genetic counseling and carrier testing are not applicable. Family members are not at increased risk of developing PNH.
Early recognition of symptoms and prompt medical evaluation represent the most important factors in preventing complications. Patients with aplastic anemia or myelodysplastic syndrome should undergo regular monitoring for PNH development, as these conditions carry higher risk.
Complications
Without treatment, PNH can cause life-threatening complications. Thrombosis (blood clots) represents the most dangerous complication, occurring in 40-60% of patients and causing death in 50% of cases. Clots commonly form in abdominal veins (hepatic, portal, mesenteric), cerebral vessels, and pulmonary arteries.
Chronic kidney disease develops in 60-80% of patients due to repeated hemoglobin exposure damaging kidney tubules. Progressive anemia can lead to heart failure and severe fatigue that prevents normal activities. Pulmonary hypertension may develop from repeated small blood clots in lung vessels.
Bone marrow failure can occur, leading to dangerous drops in white blood cells and platelets. This increases infection risk and bleeding tendencies. Some patients develop iron deficiency from chronic blood loss, while others experience iron overload from frequent transfusions.
Diagnosis
PNH diagnosis relies primarily on flow cytometry testing that detects red blood cells lacking CD55 and CD59 proteins. This test measures the percentage of PNH cells in blood samples and remains the gold standard for diagnosis.
Laboratory tests include complete blood count showing anemia and possibly low white blood cell or platelet counts. Elevated lactate dehydrogenase (LDH) indicates ongoing hemolysis. Urine tests may reveal hemoglobin, though absence doesn’t rule out PNH. Haptoglobin levels are typically low or absent.
Additional testing includes bone marrow biopsy to evaluate for aplastic anemia or myelodysplastic syndrome. Imaging studies may be needed to evaluate for blood clots if symptoms suggest thrombosis. Genetic testing isn’t routinely performed since the PIGA mutation occurs in bone marrow cells rather than inherited DNA.
The Ham test and sucrose hemolysis test were historically used but have been replaced by more accurate flow cytometry methods. Diagnosis requires detecting PNH cells comprising at least 1% of red blood cells, though higher percentages correlate with more severe disease.
Treatment
Treatment focuses on preventing complement-mediated hemolysis and managing complications. Several targeted therapies have transformed PNH management over the past two decades.
Complement inhibitors represent first-line therapy. Eculizumab was the first approved treatment, requiring intravenous infusions every two weeks. Ravulizumab offers similar efficacy with dosing every 8 weeks. Both drugs block C5 complement protein, preventing red blood cell destruction.
Newer complement inhibitors include pegcetacoplan, which targets C3 and may be more effective for some patients. Iptacopan is an oral complement inhibitor offering convenient daily dosing. Danicopan can be added to other treatments for additional hemolysis control.
Supportive care includes blood transfusions for severe anemia, though these should be minimized due to iron overload risk. Anticoagulation may be necessary for thrombosis treatment or prevention. Vaccinations against encapsulated bacteria are essential before starting complement inhibitors, as these medications increase infection risk.
Bone marrow transplantation can cure PNH but carries significant risks and is typically reserved for young patients with severe disease or those who develop aplastic anemia.
Prognosis
PNH prognosis has dramatically improved with complement inhibitor therapy. Before these treatments, 10-year survival was approximately 50%, with thrombosis causing most deaths. With modern therapy, 10-year survival exceeds 85%, and many patients experience near-normal life expectancy.
Factors affecting prognosis include percentage of PNH cells, presence of bone marrow failure, and history of thrombosis. Patients with higher PNH cell percentages typically have more severe symptoms but may respond better to treatment. Early diagnosis and treatment initiation improve outcomes.
Quality of life generally improves significantly with treatment. Fatigue reduction allows return to normal activities, while thrombosis prevention eliminates the major mortality risk. However, treatment requires lifelong therapy and regular monitoring.
Some patients achieve partial or complete remission, though this is unpredictable. Disease progression to aplastic anemia or myelodysplastic syndrome occurs in 10-20% of cases and may require bone marrow transplantation.
Quality of life
Living with PNH requires adapting to chronic symptoms and treatment demands. Fatigue management involves pacing activities, prioritizing essential tasks, and planning rest periods. Many patients can maintain employment with accommodations like flexible schedules or reduced physical demands.
Exercise should be tailored to individual capacity. Low-impact activities like walking, swimming, or yoga may be beneficial, while avoiding overexertion that could worsen fatigue. Regular gentle exercise can help combat treatment-related side effects and maintain cardiovascular health.
Diet should include iron-rich foods if deficiency develops, though some patients require iron restriction due to transfusion overload. Adequate protein supports blood cell production, while staying hydrated helps kidney function. Alcohol should be limited as it can worsen fatigue and interact with medications.
Mental health support is crucial, as chronic illness and treatment burden can lead to anxiety and depression. Counseling, support groups, and stress management techniques help patients cope. Maintaining social connections and pursuing meaningful activities enhance well-being.
Travel considerations include ensuring medication availability and identifying medical facilities at destinations. Patients on complement inhibitors need prompt medical attention for fever or signs of infection.
Pregnancy and fertility
PNH significantly increases pregnancy risks, including thrombosis, bleeding, and disease flares. Pre-pregnancy counseling is essential to optimize treatment and assess risks. Complement inhibitors like eculizumab appear safe during pregnancy and may reduce complications.
Pregnancy management requires multidisciplinary care with hematologists, obstetricians, and maternal-fetal medicine specialists. Anticoagulation may be necessary to prevent thrombosis. Close monitoring for anemia, thrombocytopenia, and signs of thrombosis is crucial throughout pregnancy and postpartum.
Fertility can be affected by chronic anemia and treatment side effects, though many patients successfully conceive. Men may experience erectile dysfunction related to smooth muscle complications. Genetic counseling can provide reassurance that PNH is not inherited.
The postpartum period carries particularly high thrombosis risk, requiring continued anticoagulation and monitoring. Breastfeeding compatibility varies by medication and should be discussed with healthcare providers.
Children
Pediatric PNH is rare, representing less than 10% of cases. Children typically present with more severe bone marrow failure and may have different symptom patterns than adults. Growth and development can be affected by chronic anemia and treatment demands.
Treatment principles remain similar to adults, though dosing adjustments and careful monitoring of growth and development are necessary. Bone marrow transplantation may be considered earlier in children given their longer life expectancy and better transplant tolerance.
Educational accommodations may be needed for fatigue, medical appointments, and cognitive effects. Psychological support helps children and families adapt to chronic illness and treatment requirements.
When to see a doctor
Seek immediate medical attention for severe abdominal pain, chest pain, severe headache, sudden shortness of breath, or neurological symptoms, as these may indicate thrombosis. High fever in patients on complement inhibitors requires urgent evaluation due to infection risk.
Schedule routine appointments for unexplained fatigue lasting more than two weeks, dark-colored urine, easy bruising, or recurrent infections. Gradual worsening of symptoms warrants medical evaluation even if not immediately dangerous.
Emergency situations include signs of stroke, heart attack, or pulmonary embolism. Patients on complement inhibitors should seek immediate care for fever, as these medications increase meningococcal infection risk.
Regular follow-up with hematologists is essential for monitoring disease activity, treatment response, and early complication detection.
Regional context
Limited specific prevalence data exists for PNH in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The global prevalence of 1-1.5 per million likely applies to these regions, though genetic factors could influence local rates.
Healthcare infrastructure and access to expensive complement inhibitor therapies may vary significantly across these regions. International collaboration and support programs may be necessary to ensure patients receive appropriate care.
The Global Medical Journal welcomes contributions from healthcare providers and researchers in these regions to better understand local PNH epidemiology, challenges, and treatment outcomes. Regional patient registries could provide valuable insights into disease patterns and treatment responses in diverse populations.
Research and clinical trials
Current research focuses on developing more convenient oral complement inhibitors, combination therapies, and treatments targeting different disease mechanisms. Gene therapy approaches aim to correct the underlying PIGA mutation in bone marrow stem cells.
Active research areas include complement inhibitors with longer dosing intervals, treatments for extravascular hemolysis, and biomarkers predicting treatment response. Clinical trials are evaluating combination therapies and treatments for patients who don’t respond adequately to current options.
Emerging therapies include factor D inhibitors, alternative complement pathway targets, and novel approaches to prevent thrombosis. Researchers are also investigating why some patients achieve remission while others require lifelong treatment.
Patients interested in clinical trials can search ClinicalTrials.gov using terms like “paroxysmal nocturnal hemoglobinuria” or “PNH.” Participation in research studies may provide access to experimental treatments while contributing to medical knowledge.
Frequently asked questions
Is PNH hereditary?
No, PNH is an acquired condition caused by spontaneous mutations in bone marrow cells. It is not inherited from parents and cannot be passed to children. Family members are not at increased risk.
Why is it called “nocturnal” if symptoms occur all day?
The name is historical and somewhat misleading. Early descriptions focused on dark morning urine, leading to the assumption that hemolysis occurred primarily at night. We now know hemolysis happens continuously, though some patients notice darker urine in the morning due to concentration overnight.
Can PNH be cured?
Bone marrow transplantation can cure PNH by replacing abnormal stem cells with healthy ones. However, transplant risks often outweigh benefits except in severe cases. Most patients achieve excellent control with complement inhibitor therapy, though this requires lifelong treatment.
How long do PNH treatments take to work?
Complement inhibitors typically reduce hemolysis within 1-2 weeks, with maximal benefit achieved within 4-8 weeks. Fatigue improvement may take longer as anemia gradually resolves. Some symptoms like kidney function may take months to improve.
What should I do if I miss a dose of my PNH medication?
Contact your healthcare provider immediately, as missed doses of complement inhibitors can lead to severe hemolysis rebound. Depending on timing, you may need to receive the dose as soon as possible or adjust the schedule. Never stop these medications without medical supervision.
Support and resources
International organizations:
- Aplastic Anemia & MDS International Foundation – Primary patient advocacy organization for PNH
- Orphanet – European database of rare diseases and orphan drugs
- National Organization for Rare Disorders (NORD) – US-based rare disease advocacy
- EURORDIS – European rare disease patient alliance
- World Health Organization – Rare Diseases
Additional resources:
- ClinicalTrials.gov – Database of clinical research studies
- GeneReviews – Expert-authored disease descriptions
- OM
Cite this page
GMJ News Desk. “Paroxysmal nocturnal hemoglobinuria.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/paroxysmal-nocturnal-hemoglobinuria/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?